IN2014DN08982A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN08982A IN2014DN08982A IN8982DEN2014A IN2014DN08982A IN 2014DN08982 A IN2014DN08982 A IN 2014DN08982A IN 8982DEN2014 A IN8982DEN2014 A IN 8982DEN2014A IN 2014DN08982 A IN2014DN08982 A IN 2014DN08982A
- Authority
- IN
- India
- Prior art keywords
- disease
- duchene
- hypertriglyceridemia
- hypercholesterolemia
- alzheimer
- Prior art date
Links
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 208000024777 Prion disease Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000013522 chelant Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648694P | 2012-05-18 | 2012-05-18 | |
| PCT/CA2013/050378 WO2013170385A1 (en) | 2012-05-18 | 2013-05-17 | Oligonucleotide chelate complex methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08982A true IN2014DN08982A (da) | 2015-05-22 |
Family
ID=49581827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8982DEN2014 IN2014DN08982A (da) | 2012-05-18 | 2013-05-17 |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9616083B2 (da) |
| EP (1) | EP2849760B1 (da) |
| JP (2) | JP6294308B2 (da) |
| KR (1) | KR101975915B1 (da) |
| CN (1) | CN104379152B (da) |
| AR (1) | AR091065A1 (da) |
| AU (1) | AU2013262415B2 (da) |
| BR (1) | BR112014028568B1 (da) |
| CA (1) | CA2873526C (da) |
| CL (1) | CL2014003135A1 (da) |
| CO (1) | CO7131388A2 (da) |
| CR (1) | CR20140522A (da) |
| CU (1) | CU20140132A7 (da) |
| CY (1) | CY1122856T1 (da) |
| DK (1) | DK2849760T3 (da) |
| DO (1) | DOP2014000263A (da) |
| EA (1) | EA034799B1 (da) |
| EC (1) | ECSP14027542A (da) |
| ES (1) | ES2767333T3 (da) |
| HR (1) | HRP20200045T1 (da) |
| HU (1) | HUE047456T2 (da) |
| IL (1) | IL235402B (da) |
| IN (1) | IN2014DN08982A (da) |
| LT (1) | LT2849760T (da) |
| MX (1) | MX360626B (da) |
| MY (1) | MY168209A (da) |
| NZ (1) | NZ701931A (da) |
| PH (1) | PH12014502484B1 (da) |
| PL (1) | PL2849760T3 (da) |
| PT (1) | PT2849760T (da) |
| RS (1) | RS59914B1 (da) |
| SG (1) | SG11201407261XA (da) |
| SI (1) | SI2849760T1 (da) |
| SM (1) | SMT202000025T1 (da) |
| TW (1) | TWI648288B (da) |
| WO (1) | WO2013170385A1 (da) |
| ZA (1) | ZA201408082B (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101896186A (zh) | 2007-10-26 | 2010-11-24 | 莱顿教学医院 | 对抗肌肉病症的方式和方法 |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| BR112014018427B1 (pt) | 2012-01-27 | 2021-11-03 | Biomarin Technologies B.V. | Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker |
| WO2014032176A1 (en) | 2012-08-30 | 2014-03-06 | Replicor Inc. | Methods for the treatment of hepatitis b and hepatitis d infections |
| HRP20231400T1 (hr) * | 2014-07-10 | 2024-02-16 | Replicor Inc. | Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d |
| EA035885B1 (ru) | 2015-04-23 | 2020-08-27 | Джерон Корпорейшн | Способы получения полинуклеотидов с использованием композиций солей поливалентных катионов |
| CN108513546A (zh) | 2015-10-28 | 2018-09-07 | 克里斯珀医疗股份公司 | 用于治疗杜氏肌营养不良症的材料和方法 |
| KR20180095694A (ko) * | 2015-12-23 | 2018-08-27 | 퀸스랜드 유니버시티 오브 테크놀로지 | 핵산 올리고머 및 이의 용도 |
| KR102824513B1 (ko) * | 2016-07-05 | 2025-06-25 | 바이오마린 테크놀로지스 비.브이. | 유전적 장애 치료를 위한, 특징이 개선된, 비사이클릭 스캐폴드 모이어티를 포함하는 프리-mrna 스플라이스 스위칭 또는 조정 올리고뉴클레오티드 |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2022229350A2 (en) | 2021-04-30 | 2022-11-03 | Tirmed Pharma Ab | Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69430740T2 (de) * | 1993-04-01 | 2003-02-06 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONNUKLEOTIDE DIE MIT DER mRNA CAP AKTIVITÄT INTERFERIEREN UND DIE TRANSLATION INHIBIEREN |
| US20020166764A1 (en) * | 1997-08-12 | 2002-11-14 | University Of Southern California | Electrochemical sensor devices and methods for fast, reliable, and sensitive detection and quantitation of analytes |
| US20050020525A1 (en) * | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CA2498777C (en) * | 2002-09-13 | 2015-01-13 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
| CN1694959A (zh) * | 2002-09-13 | 2005-11-09 | 雷普利瑟公司 | 非序列互补的抗病毒寡核苷酸 |
| WO2006042418A1 (en) * | 2004-10-19 | 2006-04-27 | Replicor Inc. | Antiviral oligonucleotides |
| US20090215873A1 (en) | 2005-09-29 | 2009-08-27 | Andrew Vaillant | Therapeutic Molecules and their Uses |
| EP2057284A4 (en) * | 2006-08-04 | 2011-06-29 | Isis Pharmaceuticals Inc | COMPOSITIONS AND METHODS OF MODULATING JNK PROTEINS |
| WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
| US8404659B2 (en) * | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
| WO2010107838A1 (en) * | 2009-03-16 | 2010-09-23 | Isis Pharmaceuticals, Inc. | Targeting apolipoprotein b for the reduction of apolipoprotein c-iii |
| CA2764683A1 (en) * | 2009-05-28 | 2010-12-02 | Joseph Collard | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| CA2855690C (en) | 2010-08-20 | 2015-08-25 | Replicor Inc. | Oligonucleotide chelate complexes |
-
2013
- 2013-05-16 AR ARP130101695A patent/AR091065A1/es not_active Application Discontinuation
- 2013-05-17 RS RS20200065A patent/RS59914B1/sr unknown
- 2013-05-17 SI SI201331646T patent/SI2849760T1/sl unknown
- 2013-05-17 MY MYPI2014003113A patent/MY168209A/en unknown
- 2013-05-17 BR BR112014028568-3A patent/BR112014028568B1/pt active IP Right Grant
- 2013-05-17 PT PT137915849T patent/PT2849760T/pt unknown
- 2013-05-17 CN CN201380025475.XA patent/CN104379152B/zh active Active
- 2013-05-17 EP EP13791584.9A patent/EP2849760B1/en active Active
- 2013-05-17 LT LTEP13791584.9T patent/LT2849760T/lt unknown
- 2013-05-17 MX MX2014013885A patent/MX360626B/es active IP Right Grant
- 2013-05-17 NZ NZ701931A patent/NZ701931A/en unknown
- 2013-05-17 ES ES13791584T patent/ES2767333T3/es active Active
- 2013-05-17 CA CA2873526A patent/CA2873526C/en active Active
- 2013-05-17 IN IN8982DEN2014 patent/IN2014DN08982A/en unknown
- 2013-05-17 SM SM20200025T patent/SMT202000025T1/it unknown
- 2013-05-17 US US13/896,427 patent/US9616083B2/en not_active Expired - Fee Related
- 2013-05-17 WO PCT/CA2013/050378 patent/WO2013170385A1/en not_active Ceased
- 2013-05-17 EA EA201401276A patent/EA034799B1/ru unknown
- 2013-05-17 KR KR1020147035251A patent/KR101975915B1/ko active Active
- 2013-05-17 DK DK13791584.9T patent/DK2849760T3/da active
- 2013-05-17 HR HRP20200045TT patent/HRP20200045T1/hr unknown
- 2013-05-17 AU AU2013262415A patent/AU2013262415B2/en active Active
- 2013-05-17 JP JP2015511876A patent/JP6294308B2/ja not_active Expired - Fee Related
- 2013-05-17 SG SG11201407261XA patent/SG11201407261XA/en unknown
- 2013-05-17 HU HUE13791584A patent/HUE047456T2/hu unknown
- 2013-05-17 TW TW102117593A patent/TWI648288B/zh active
- 2013-05-17 PL PL13791584T patent/PL2849760T3/pl unknown
-
2014
- 2014-10-30 IL IL235402A patent/IL235402B/en unknown
- 2014-11-04 ZA ZA2014/08082A patent/ZA201408082B/en unknown
- 2014-11-06 PH PH12014502484A patent/PH12014502484B1/en unknown
- 2014-11-14 CR CR20140522A patent/CR20140522A/es unknown
- 2014-11-17 CU CU2014000132A patent/CU20140132A7/es unknown
- 2014-11-17 EC ECIEPI201427542A patent/ECSP14027542A/es unknown
- 2014-11-18 CL CL2014003135A patent/CL2014003135A1/es unknown
- 2014-11-18 DO DO2014000263A patent/DOP2014000263A/es unknown
- 2014-11-19 CO CO14254326A patent/CO7131388A2/es unknown
-
2017
- 2017-11-02 JP JP2017212508A patent/JP2018058853A/ja active Pending
-
2020
- 2020-01-21 CY CY20201100051T patent/CY1122856T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08982A (da) | ||
| IL277470A (en) | Manufacturing method for pharmaceutical preparations for the treatment of diseases caused by CFTR | |
| SG11201503365YA (en) | Pharmaceutical compositions for the treatment of cftr mediated diseases | |
| MD4589B1 (ro) | Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C | |
| HRP20182069T1 (hr) | Farmaceutski pripravci za liječenje alzheimerove bolesti | |
| SI2939665T1 (sl) | Farmacevtska sestava za zdravljenje HIV infekcij | |
| PH12014502551A1 (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| EP2969011A4 (en) | Rapidly adaptable nano therapeutics for treatment of infectious disease | |
| SMT201700138T1 (it) | Composizione farmaceutica per il trattamento della distrofia muscolare di duchenne |